In our latest ASCO 2018 Preview series we take a look at some of the key highlights from urothelial and bladder cancers and look at how new developments in this space are progressing.
Historically in oncology, we see initial trials begin in advanced stage disease especially in the refractory metastatic setting and move up into earlier lines of therapy later as safety and efficacy become more established.
This situation has been very much the case in urothelial carcinomas, including bladder, penile, renal pelvis, ureter and transitional cell cancers. With the approval of pembrolizumab and atezolizumab in the relapsed setting following cisplatin therapy, much of the focus has now turned to earlier stage disease.
In our latest Preview, we explore some of the key combinations and look at whether or not they are more promising in terms of outcomes than the monotherapy readouts we have seen to date. There’s a lot to cover and digest…